Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2017
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:can_be_combined_with |
gptkb:pibrentasvir
|
| gptkbp:class |
antiviral
|
| gptkbp:clinical_trial |
Phase 3
demonstrated high efficacy well tolerated in diverse populations |
| gptkbp:clinical_use |
chronic hepatitis C
|
| gptkbp:contraindication |
severe liver disease
|
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:drug_interactions |
with anticonvulsants
with immunosuppressants with statins |
| gptkbp:duration |
8 to 12 weeks
|
| gptkbp:effective_date |
approved in multiple countries
|
| gptkbp:excretion |
feces
|
| gptkbp:formulation |
fixed-dose combination
|
| https://www.w3.org/2000/01/rdf-schema#label |
glecaprevir
|
| gptkbp:interacts_with |
with strong CYP3 A inducers
with strong CYP3 A inhibitors |
| gptkbp:invention |
patented
|
| gptkbp:is_a_guide_for |
recommended by WHO
|
| gptkbp:is_effective_against |
over 95% cure rate
|
| gptkbp:is_monitored_by |
liver function tests recommended
|
| gptkbp:marketed_as |
gptkb:Mavyret
|
| gptkbp:mechanism_of_action |
NS3/4 A protease inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:patient_population |
adults
children over 12 years |
| gptkbp:pharmacokinetics |
high bioavailability
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_guidance_on |
once daily
AASLD guidelines EASL guidelines |
| gptkbp:research_focus |
HCV genotype 1-6
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
gptkb:anemia
fatigue headache nausea diarrhea rash insomnia liver enzyme elevation |
| gptkbp:targets |
HCV (Hepatitis C virus)
|
| gptkbp:treatment |
sustained virologic response
with pibrentasvir |
| gptkbp:treatment_limitation |
not for use in pregnancy
not for use in decompensated cirrhosis not for use in severe renal impairment |
| gptkbp:type_of_care |
important for treatment success
|
| gptkbp:used_for |
treatment of hepatitis C
|
| gptkbp:bfsParent |
gptkb:virus
|
| gptkbp:bfsLayer |
4
|